On Mar 31, 2021, at 9:47 PM, Alex Balashov
<[email protected]> wrote:
For immediate release:
GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership
with Posner | Palner Pharmaceuticals, are pleased to announce the
eagerly anticipated start of Phase III clinical trials of Kamailio
DMQ module replication.
In this stage of the investigation of the promising replication
scheme, which was developed in record time, DMQ will be tested in a
rigourous, double-blind, controlled CI/CD process for large-scale
efficacy and continually monitored for safety in shorter and longer
terms.
The now-concluded second phase established basic safety and Phase 2b
entailed a dose-finding study for the optimal number of batched
`dmq_usrloc` contacts per kilogram of cloud computing resource.
The main cohort of the main sequence of the Phase III trial will
enroll 380 randomly selected, statistically representative Floridian
SIP registrars and
5700 SIP dialogs, also in the state of Florida. When asked about the
disparity in the number of registrars versus dialogs, Alex Balashov
of Evariste said, "It is reflective of the small number of SIP
registrars in Florida; not to be indelicate, but consider the median
age of the population."
As previously remarked upon in proceedings of the World SIP
Organisation (WSO), the choice of Florida as a venue attracted some
questions. We asked Fred Posner of Posner | Palner about the clinical
background informing this choice of replication study cohort:
"Florida is a good place to find eventual consistency failures; the
open climate and reluctance to accept traditional data integrity
science would have sealed the deal, but when people started to drink
bleach here, I saw an opportunity."
Evariste and Posner | Palner are aiming for a US Food & Drug
Administration EUA (Emergency Use Authorisation) for DMQ replication
as a prophylactic data redundancy and failover measure to ward off
the development of moderate to severe viral Sonus Haemorrhagic Fever
symptoms.
Phase II studies have painted a promising a picture of the DMQ
architecture's ability to reduce moderate to severe symptoms and
associated 28-day mortality by more than 90%, albeit over a small
sample size and in enterprise patients with known pre-existing
comorbidities such as Session Border Controller and BroadSoft
Multi-System Inflammatory Syndrome. Phase III trials seek to bolster
quantums of broader efficacy, including efficacy for localised
outbreaks of small to medium business softswitch.
Of the control group, Balashov said, "They will receive a standard
pipe-to-/dev/null placebo protocol, but with identical '200 OK'
confirmation messages. We proudly developed this approach in early
2020 in consultation with the highest levels of the Trump
presidential administration; it is called TENP, or 'The Emperor's New
Potion.' It is a successor to that administration's previous approved
placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
Despite speculative autism and packet fragmentation claims by Florida
Governor Ron DeSantis, Balashov was quick to provide reassurance
about side effects from DMQ in the Phase III trial.
"The incidence of severe allergies to plain-text UDP was within
standard deviation over the mean for all insecure replication, and
there's support for other transports on the way. Anyway, we have a
robust adverse effects reporting system in our issue tracker and
solid surveillance. Don't let partisan politics dissuade you from
allowing request lines with the KDMQ method."
Other industry sources have reported that DMQ is not the only
replication investigation undertaken by Evariste and Posner | Palner,
although it is the only prophylactic suitable for the early infection
development and inflammatory phases of a broad class of SBC-complex
syndromes typically afflicting service providers. A recent IETF
preprint by the same authors has shown high-quality preliminary data
suggesting statistically significant improvement in morbidity
outcomes from Perimeta and Nokia via a later-stage therapeutic
intervention with a monoclonal, monorepo Github cocktail administered
intravenously.
--
Alex Balashov | Principal | Evariste Systems LLC
Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free)
Web: http://www.evaristesys.com/, http://www.csrpswitch.com/
_______________________________________________
VoiceOps mailing list
[email protected]
https://puck.nether.net/mailman/listinfo/voiceops
